Merck’s COVID-19 oral pill molnupiravir has a mechanism of action that can work against Omicron and any other variant, a company executive said on Monday.
“We’re very confident that it will effect Omicron ... This mechanism in molecule (will) work for Omicron, and I would imagine against any variant that comes up,” Dean Li, president of Merck Research Laboratories, said at J.P. Morgan’s annual healthcare conference.
